Site Members can sign up for company wide alerts
Investigation Overview
October 21, 2014 (Update) - On September 26, 2014, Repros Therapeutics Inc announced that it had been granted a Type B Pre-NDA meeting with the FDA in the first half of November, 2014. Repros Therapeutics Inc said that it would seek guidance during this Type B meeting on its planned New Drug Application (NDA) for Androxal for the treatment of secondary hypogonadism with preservation ...
You must register (for free) or login to view the entire investigation.